Mirae Asset Global Etfs Holdings Ltd. Cardiff Oncology, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 33,678 shares of CRDF stock, worth $73,754. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,678
Previous 34,319
1.87%
Holding current value
$73,754
Previous $107,000
0.93%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CRDF
# of Institutions
126Shares Held
25.8MCall Options Held
1.01MPut Options Held
293K-
Vanguard Group Inc Valley Forge, PA3.73MShares$8.17 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$5.76 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$5.53 Million0.02% of portfolio
-
Laurion Capital Management LP New York, NY1.8MShares$3.94 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA1.5MShares$3.28 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $94.9M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...